Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Personal Products Industry Analysis

UpdatedJun 11, 2026
DataAggregated Company Financials
Companies109
  • 7D6.2%
  • 3M1.8%
  • 1Y-16.0%
  • YTD-10.4%

Over the last 7 days, the Personal Products industry has risen 6.2%, driven by gains from Kenvue of 7.2%. In the same time, Yatsen Holding was down 13%. In the past year, the industry is down 16%. Earnings are forecast to grow by 35% annually.

Industry Valuation and Performance

Has the U.S. Personal Products Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 12 Jun 2026US$81.6bUS$48.3bUS$699.1m18.1x116.7x1.7x
Sun, 10 May 2026US$81.7bUS$48.3bUS$684.5m17.9x119.3x1.7x
Tue, 07 Apr 2026US$73.9bUS$48.2bUS$613.9m20.6x120.3x1.5x
Thu, 05 Mar 2026US$88.1bUS$48.2bUS$797.2m21.1x110.5x1.8x
Sat, 31 Jan 2026US$94.0bUS$47.6bUS$350.0m22.7x268.6x2x
Mon, 29 Dec 2025US$90.9bUS$47.6bUS$351.2m22x258.9x1.9x
Wed, 26 Nov 2025US$84.3bUS$47.6bUS$357.7m22.8x235.5x1.8x
Fri, 24 Oct 2025US$89.0bUS$47.7bUS$290.6m21.3x306.2x1.9x
Sun, 21 Sep 2025US$94.4bUS$47.6bUS$304.0m21.5x310.4x2x
Tue, 19 Aug 2025US$100.1bUS$48.2bUS$531.1m20.1x188.5x2.1x
Thu, 17 Jul 2025US$98.8bUS$48.0bUS$109.7m17.4x900.4x2.1x
Sat, 14 Jun 2025US$96.4bUS$48.0bUS$109.5m17.1x880.6x2x
Mon, 12 May 2025US$92.9bUS$48.0bUS$94.0m16.9x988.1x1.9x
Wed, 09 Apr 2025US$80.4bUS$48.7bUS$557.2m20.8x144.4x1.7x
Fri, 07 Mar 2025US$93.8bUS$49.0bUS$331.2m26x283.2x1.9x
Sun, 02 Feb 2025US$98.8bUS$49.3bUS$1.5b27.5x67x2x
Tue, 31 Dec 2024US$97.8bUS$49.3bUS$1.5b27x66.3x2x
Thu, 28 Nov 2024US$103.7bUS$49.3bUS$1.5b29.4x70.4x2.1x
Sat, 26 Oct 2024US$105.2bUS$49.5bUS$1.6b24.8x65.1x2.1x
Mon, 23 Sep 2024US$106.3bUS$49.5bUS$1.6b23.1x64.9x2.1x
Wed, 21 Aug 2024US$110.2bUS$49.5bUS$1.8b27.1x62.9x2.2x
Fri, 19 Jul 2024US$108.2bUS$49.0bUS$2.4b22.3x44.7x2.2x
Sun, 16 Jun 2024US$110.8bUS$49.0bUS$2.4b23.8x45.7x2.3x
Tue, 14 May 2024US$122.6bUS$48.8bUS$2.5b25.6x49.9x2.5x
Thu, 11 Apr 2024US$129.1bUS$48.8bUS$2.5b25.6x50.9x2.6x
Sat, 09 Mar 2024US$133.1bUS$49.1bUS$2.4b29.1x55x2.7x
Mon, 05 Feb 2024US$127.5bUS$50.1bUS$2.6b24.3x50x2.5x
Wed, 03 Jan 2024US$129.2bUS$49.9bUS$2.6b27.1x49x2.6x
Fri, 01 Dec 2023US$115.2bUS$49.9bUS$2.6b25.2x44.2x2.3x
Sun, 29 Oct 2023US$107.3bUS$50.1bUS$3.3b24.5x32.6x2.1x
Tue, 26 Sep 2023US$124.2bUS$50.0bUS$3.3b24.3x37.8x2.5x
Thu, 24 Aug 2023US$133.9bUS$50.0bUS$3.3b20.2x40.9x2.7x
Sat, 22 Jul 2023US$145.9bUS$49.8bUS$3.1b23.6x47.6x2.9x
Mon, 19 Jun 2023US$156.4bUS$49.3bUS$3.1b22.3x49.9x3.2x
Price to Earnings Ratio

49.9x


Total Market Cap: US$156.4bTotal Earnings: US$3.1bTotal Revenue: US$49.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Personal Products Industry Price to Earnings3Y Average 171.6x202420252026
Current Industry PE
  • Investors are pessimistic on the American Personal Products industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 117x which is lower than its 3-year average PE of 172x.
  • The 3-year average PS ratio of 2.2x is higher than the industry's current PS ratio of 1.7x.
Past Earnings Growth
  • The earnings for companies in the Personal Products industry have declined 39% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Consumer Staples industry?

US Market-4.05%
Consumer Staples3.68%
Personal Products6.15%
Personal Products6.15%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
KVUE KenvueUS$18.077.0%
+US$2.3b		-18.0%PE21.4x
EL Estée Lauder CompaniesUS$88.026.2%
+US$1.9b		25.8%PS2.1x
ELF e.l.f. BeautyUS$60.6818.0%
+US$549.2m		-52.8%PE137x
IPAR InterparfumsUS$100.1512.7%
+US$360.9m		-29.2%PE18.9x
COTY CotyUS$2.039.7%
+US$158.5m		-59.6%PS0.3x

Latest News

EL
US$88.02
Estée Lauder Companies
7D
6.2%
1Y
25.8%
IPAR
US$100.15
Interparfums
7D
12.7%
1Y
-29.2%
Seeking Alpha • Jun 10

Interparfums: A Fine Fragrance Machine, But 2026 Is A Bridge Year

Summary Interparfums remains a high-quality fragrance company with a diversified license portfolio, strong cash flows, and a conservative balance sheet. 2026 guidance projects flat sales ($1.48B) and lower EPS ($4.85), tempering near-term growth expectations and justifying a Hold rating. Q1 2026 results confirmed solid gross margins (65.1%) and cash flow discipline, but operating margins contracted due to rising SG&A expenses. At ~19x 2026E EPS and a base-case fair value of $89, IPAR offers balanced risk/reward; existing holders can wait, but new buyers should seek a better entry or growth clarity. Read the full article on Seeking Alpha
ODD
US$10.96
Oddity Tech
7D
8.8%
1Y
-85.2%
KVUE
US$18.07
Kenvue
7D
7.0%
1Y
-18.0%
Narrative Update • Jun 08

KVUE: Future Returns Will Reflect Merger Progress And Legal Earnings Balance

Analysts slightly lifted their fair value estimate for Kenvue to $19.50, a modest move supported by small tweaks to discount rate, revenue growth, profit margin and future P/E assumptions, even as recent Street research from Citi, Barclays and UBS reflects more cautious price targets. Analyst Commentary Recent price target trims of around $1 from several firms signal that the Street is fine tuning expectations rather than making a wholesale shift in its view on Kenvue.
ELF
US$60.68
e.l.f. Beauty
7D
18.0%
1Y
-52.8%
EPC
US$21.65
Edgewell Personal Care
7D
9.6%
1Y
-12.8%
Narrative Update • Jun 06

EPC: Share Repurchases And Updated Outlook Will Drive Future Upside Potential

Analysts have nudged their price target on Edgewell Personal Care from about $24.17 to $24.50, reflecting updated assumptions around discount rates, revenue trends, profit margins and the stock's future P/E. What's in the News Edgewell Personal Care reported that from January 1, 2026 to March 31, 2026, it repurchased 224,000 shares, representing 0.48% of shares, for a total of US$15.01 million under its existing buyback program.
MED
US$11.92
Medifast
7D
-2.9%
1Y
-9.4%
Narrative Update • Jun 06

MED: Leadership Transition And Margin Outlook Will Shape Balanced Future Profile

Analysts have modestly adjusted their price target on Medifast, reflecting updated views on the discount rate, expected profit margins near 8.1%, and an anticipated P/E around 9.7x, which together suggest a slightly different risk and valuation profile for the stock. What's in the News The board has appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026.
HLF
US$12.20
Herbalife
7D
7.1%
1Y
47.7%
Narrative Update • Jun 03

HLF: Refinancing And Margin Improvement Will Support Turnaround Despite Weak EBITDA Guidance

Narrative update on Herbalife Analysts have raised their price target on Herbalife by $2, citing research that points to updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts raising their price target by US$2 are signaling a more constructive view on how Herbalife’s valuation lines up with its fundamentals.
COTY
US$2.03
Coty
7D
9.7%
1Y
-59.6%
Narrative Update • Jun 02

COTY: Prestige Margin Execution And New Launches Will Support Future Earnings Power

Analysts have nudged Coty's implied fair value slightly lower to about $6.70 per share, while adjusting P/E and margin assumptions and updating price targets with a series of recent $0.25 to $1.00 moves across the Street. Analyst Commentary Recent research has been mixed, with some firms trimming targets by US$0.50 to US$1.00 and others nudging them higher by US$0.25 to US$0.60.
NAGE
US$3.43
Niagen Bioscience
7D
-2.0%
1Y
-75.7%
Narrative Update • Jun 02

NAGE: Core Demand And Injectables Will Support Future Buyback Driven Upside

Analysts have trimmed their average price target on Niagen Bioscience by $1 to $12.60, reflecting updated models that incorporate modest adjustments to discount rates, revenue growth, profit margin assumptions, and a slightly lower future P/E multiple. Analyst Commentary Recent Street research around Niagen Bioscience centers on how updated models reconcile the current share price with revised assumptions for growth, profitability, and valuation multiples.
CABR
US$1.09
Caring Brands
7D
-14.8%
1Y
n/a
BHST
US$3.20
BioHarvest Sciences
7D
-1.5%
1Y
-58.2%
MEHA
US$0.042
Functional Brands
7D
-52.1%
1Y
n/a
BNKK
US$1.41
Bonk
7D
-20.3%
1Y
-83.4%
UPXI
US$0.90
Upexi
7D
-11.8%
1Y
-92.9%
AXIL
US$6.48
AXIL Brands
7D
-7.4%
1Y
19.6%